This programme is subject to change and will be updated regularly
Clinical Trial Coordinator Group Meeting - Monday 3 May
NZNO Programme - Tuesday 4 May
Monday 3 May 2010
| 8.30am - 6.00pm |
Registration Desk Open You will be able to collect your registration pack from the Registration Desk located in the Langham Hotel Great Room Pre Function Foyer. |
| 9.00am - 5.00pm |
Clinical Trials Co-ordinators Meeting Great Room 4,The Langham Hotel (Note: Registrations open from 8.30am) |
| 10.15am - 2.00pm |
Genitourinary Special Interest Group Meeting Matai Room, Langham Hotel |
| 2.30pm - 5.00pm |
NZACS Meeting Matai Room, Langham Hotel |
| 12.00pm - 5.00pm |
Exhibitor Pack In |
| 6.00pm - 7.30pm |
Roche Welcome Reception The Great Room 2&3, The Langham Hotel |
Tuesday 4 May 2010
| 7.00am |
Registration Desk Open Pre Function Foyer, The Langham Hotel Pre session tea and coffee amongst exhibition |
|
6.25am - 7.30am |
Fun Run/Walk Lead by George Laking Meet outside the main entrance of The Langham Hotel at 6.25am for a 6.30am prompt departure. | |
| 8.30am - 9.00am |
NZSO and NZNO combined Conference Welcome |
Great Room 1 |
| 9.00am - 10.00am |
New Zealand Cancer Researchers, Who are we? What do we do? This session will highlight regional cancer networks Chair: Dr Nuala Helsby Professor Michael Eccles: Cancer Research in Otago Assoc. Professor Bridget Robinson: Cancer Research in Canterbury Professor Michael Berridge: Cancer Research in Wellington Dr Michael Jameson: Cancer Research in Waikato Dr Nuala Helsby: Cancer Research in Auckland |
Great Room 1 |
| 10.00am - 10.30am | Morning Tea & Exhibition | |
10.30am - 11.30am |
Harnessing Transposons for Cancer Gene Discovery: Leukemias and Lymphomas Professor Neal Copeland |
Great Room 1 |
| 11.30am - 1.00pm |
Eli Lilly Award Oral Presentations: Chair: Dr Peter Fong Untangling the causes of MEK inhibitor resistance in melanoma cell lines Clare Stones T cell mediated immune responses in colorectal cancer patients Adam Girardin Effect of tumour burden on CYP2C19 drug metabolising activity in patients Wing –Yee Lo Survival outcome of patients with newly diagnosed GBM: a single-centre experience Dr Catherine Han New Zealand wide Audit of Erlotinib use in advanced Non Small Cell Lung Cancer Dr Aneta Suder Mortality Post Systematic Anti-Cancer Therapy in the Auckland Region: A Clinical Audit Dr Sanjeev Deva |
|
| 1.00pm - 2.00pm | Lunch & Exhibition | |
2.00pm - 3.00pm |
|
Great Room 1 |
| 3.00pm - 3.30pm | Afternoon Tea & Exhibition | |
3.30pm - 5.00pm |
Fostering a culture of collaborative cancer research between clinicians and laboratory scientists in New Zealand
Chair: Associate Professor Cristin Print Introduction from Associate Professor Cristin Print A Clinical Trials Perspective Professor Michael Findlay A Nursing Perspective Gayle Jameson A Medical Oncology Trainee Perspective Dr Ben Lawrence A Surgical Trainee Perspective Dr Deborah Wright A Senior Scientist’s Perspective Professor Bruce Baguley Discussion |
|
| 5.00pm - 6.00pm |
NZSO AGM |
Great Room 1 |
| 7.30pm - midnight |
GlaxoSmithKline Conference Dinner The Langham Hotel Incorporating the presentation of: The NZSO Translational Research Award and The Best presentation by a trainee or young member of the NZSO Sponsored by Eli Lilly | |
Wednesday 5 May 2010
| 8.00am |
Registration Desk Open Pre session tea and coffee amongst exhibition | ||
8.30am - 10.00am |
Tissue banking in New Zealand: The Experiences of the Christchurch Cancer Society Tissue Bank The Middlemore Tissue Bank: A new tissue banking initiative Collaborative initiatives that are changing the face of cancer research Discussion |
| |
| 10.00am - 10.30am | Morning Tea & Exhibition | ||
10.30am - 11.30am |
Clinical Research Relevant to Optimal Use of Medicines Professor John Simes Chair: Professor Michael Findlay Proudly sponsored by  |
||
11.30am - 12.45pm |
Concurrent Sessions: Choose one of the following two sessions to attend Pre Clinical Oral Presentations Chair: Dr Nuala Helsby The effect of NVP- BEZ235 on tamoxifen resistant breast cancer cells Dr Euphemia Leung Tumour diffusion properties of nitroimidazole hypoxia markers Dr Frederick Pruijn Immunotherapy in a Murine Model of Metastatic Breast Cancer. Dr Melanie McConnell Targeting chemoresistant cells to improve immunotherapy for glioma. Martin Hunn Exploiting activity of NKT cells to enhance potency of anti-cancer vaccines Dr Ian Hermans Clinical Oral Presentations Chair: Dr George Laking TH-302, a novel tumor-selective hypoxia-activated prodrug (HAP): Phase 1 safety and activity as monotherapy and in combination with gemcitabine, docetaxel, pemetrexed and doxorubicin Virginia Langmuir Prognosis of breast cancer using simple DNA markers. Paul Oei The effects of sunitinib and sorafenib on bone pain in patients with bone metastases from renal cell carcinoma Dr Reuben Broom ACC Treatment Injury: Complications, Adverse Events and the Insurance Perspective Rachel Taylor The Voice of Experience: results from Cancer Control New Zealand's first national cancer care survey Inga O'Brien |
| |
| 12.45pm - 1.45pm | Lunch & Exhibition | ||
1.45pm - 3.45pm |
Industry and Public Research Partnerships Speakers will reflect on what they see as NZ's oncology research strengths, and will describe the kind of research activity their organisations support Chair: Dr George Laking Dr Douglas Ormrod, Programme Manager, Genesis Oncology Trust Mr John Harman, Trustee, Breast Cancer Research Trust Dr Vernon Choy, Health Research Council of New Zealand Andrea Grant, Roche Products (New Zealand) Ltd Matthew Brougham, Chief Executive Officer PHARMAC Wrap up and Conference Close |
| |
| Latest Updates |
|
Thank you to everyone who attended the Conference, we hope you found it valuable and enjoyable. |
| The Venue |
 |
|
The Langham Hotel Auckland |